Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

September 19, 2025

Study Completion Date

March 20, 2026

Conditions
Thrombotic Microangiopathy
Interventions
BIOLOGICAL

Ravulizumab

Weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.

OTHER

Placebo

Matching placebo

OTHER

Best supportive care

Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).

Trial Locations (67)

1200

Research Site, Brussels

3050

Research Site, Parkville

4032

Research Site, Chênée

5530

Research Site, Yvoir

8000

Research Site, Bruges

10408

Research Site, Goyang-si

12462

Research Site, Athens

15232

Research Site, Pittsburgh

18014

Research Site, Granada

20246

Research Site, Hamburg

26504

Research Site, Pátrai

27705

Research Site, Durham

28007

Research Site, Madrid

28034

Research Site, Madrid

28040

Research Site, Madrid

28046

Research Site, Madrid

29010

Research Site, Málaga

31008

Research Site, Pamplona

31096

Research Site, Halfa

33100

Research Site, Udine

33612

Research Site, Tampa

37007

Research Site, Salamanca

38043

Research Site, La Tronche

41013

Research Site, Seville

48236

Research Site, Grosse Pointe Farms

49033

Research Site, Angers

52621

Research Site, Ramat Gan

57010

Research Site, Thessaloniki

89081

Research Site, Ulm

98109

Research Site, Seattle

200127

Research Site, Shanghai

215006

Research Site, Suzhou

300020

Research Site, Tianjin

05403-000

Research Site, Cerqueira César

88034-000

Research Site, Florianópolis

17210-080

Research Site, Jaú

90035-903

Research Site, Porto Alegre

90110-270

Research Site, Porto Alegre

20230-130

Research Site, Rio de Janeiro

15090-000

Research Site, São José do Rio Preto

05.403-010

Research Site, São Paulo

T2N 4N1

Research Site, Calgary

06200

Research Site, Nice

00168

Research Site, Roma

010-8543

Research Site, Akita

446-8602

Research Site, Anjo

260-0877

Research Site, Chiba

960-1295

Research Site, Fukushima

259-1193

Research Site, Isehara-shi

710-8602

Research Site, Kurashiki-shi

105-8470

Research Site, Minatoku

700-8558

Research Site, Okayama

545-8586

Research Site, Osaka

589-8511

Research Site, Osakasayama-shi

060-8638

Research Site, Sapporo

565-0871

Research Site, Suita-shi

305-8576

Research Site, Tsukuba

641-8510

Research Site, Wakayama

9713 GZ

Research Site, Groningen

03080

Research Site, Seoul

03722

Research Site, Seoul

06351

Research Site, Seoul

08036

Research Site, Barcelona

08908

Research Site, L'Hospitalet de Llobregat

141 57

Research Site, Huddinge

W12 0HS

Research Site, London

NG5 1PB

Research Site, Nottingham

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY